Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641
Abstract
Twenty-five women with advanced histologically documented stage IV recurrent or inoperable breast cancer were enrolled on a phase II study of echinomycin administered at a dose of 1.2 mg/m2 intravenously over 30 minutes weekly for 4 weeks followed by a two week rest period. Seventy-six percent of patients had visceral dominant disease at study entry and all patients had previously received chemotherapy. One of 21 eligible patients had a partial response lasting 147 days. The median survival for this group of patients was 5.9 months and the median time to treatment failure was 1.7 months. Nausea and vomiting was the primary toxic effect and was severe or life-threatening in 43% of patients. Transient elevation of liver enzymes occurred in 30% of patients. Bone marrow suppression was not significant. Echinomycin as employed in this study did not demonstrate significant antitumor activity in previously treated patients with advanced breast cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CrEL-echinomycin caused severe nausea and vomiting, constituting its dose-limiting toxicity.
“CrEL-echinomycin also caused severe nausea and vomiting, constituting its dose-limiting toxicity11, 12, 15-21.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [18]
Clinical development of echinomycin was discontinued because it was not effective for patients with solid tumors refractory to all available treatments.
“However, clinical development was discontinued because echinomycin was not found to be effective for patients with solid tumors that were refractory to all available treatments.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [18]
CrEL-echinomycin caused hypersensitivity reactions in clinical trials.
“in clinical trials with CrEL-echinomycin, hypersensitivity reactions were observed12, 18, 19, 21-23”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [18]
Clinical studies have provided considerable safety data for echinomycin.
“Clinical studies have provided considerable safety data for echinomycin10-12, 14-18, 41-45”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [18]
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works
Echinomycin: a bifunctional intercalating antibiotic
Waring, M. J., & Wakelin, L. P. G. (1974) · Nature · doi:10.1038/252653a0 · Cited by 284 · see citing works
The binding of echinomycin to deoxyribonucleic acid
Wakelin, L. P. G., & Waring, M. J. (1976) · Biochemical Journal · doi:10.1042/bj1570721 · Cited by 161 · see citing works
Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Einhorn, L. H., Nagy, C. K., Werner, K., & Finn, A. L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.4.731 · Cited by 80 · see citing works
Echinomycin: The first bifunctional intercalating agent in clinical trials
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985) · Investigational New Drugs · doi:10.1007/bf00170766 · Cited by 61 · see citing works
Structure of quinomycin antibiotics.
Martin, D. G., MIZSAK, S. A., Biles, C., STEWART, J. C., Baczynskyj, L., & Meulman, P. A. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.332 · Cited by 56 · see citing works
Phase I study of echinomycin administered on an intermittent bolus schedule.
Jh, H., McFadden, M., Andrews, W. G., Pj, B., Ahlgren, J. D., & Pv, W. (1985) · PubMed · Cited by 16 · see citing works
Kuhn, J. G., Von Hoff, D. D., Hersh, M., Melink, T., Clark, G. M., Weiss, G. R., & Coltman, C. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90123-5 · Cited by 14 · see citing works
Cytotoxic Activity of Echinomycin in a Human Tumor Cloning System
Lathan, B., & Hoff, D. D. V. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.191 · Cited by 14 · see citing works
(1987) · PubMed · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
Yagoda, A., Petrylak, D. P., & Thompson, S. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00489-4 · Cited by 206 · see citing works
Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 164 · see citing works
Dawson, S. J., Malkinson, J. P., Paumier, D., & Searcey, M. (2006) · Natural Product Reports · doi:10.1039/b516347c · Cited by 99 · see citing works
Hayes, D. F., Yamauchi, H., Broadwater, G., Cirrincione, C., Rodrigue, S. P., Berry, D. A., Younger, J., Panasci, L., Millard, F. E., Duggan, D. B., et al. (2001) · PubMed · Cited by 95 · see citing works
Self-citationAlshaer, W., Zraikat, M. S., Amer, A., Nsairat, H., Lafi, Z., Alqudah, D. A., Qadi, E. A., Alsheleh, T., Odeh, F., Alkaraki, A., et al. (2019) · RSC Advances · doi:10.1039/c9ra05636j · Cited by 65 · see citing works
Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Ponnurangam, S., Dandawate, P. R., Dhar, A., Tawfik, O. W., Parab, R., Mishra, P. D., Ranadive, P., Sharma, R. K., Mahajan, G., Umar, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6560 · Cited by 64 · see citing works
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, S. M. U., Streit, S., Huynh, B. T., Hana, C. K., Abraham, A. N. J., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042060 · Cited by 57 · see citing works
Notch signaling, hypoxia, and cancer
Guo, M., Niu, Y., Xie, M., Liu, X., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1078768 · Cited by 48 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
Liu, Y., Nelson, M. V., Bailey, C. M., Zhang, P., Zheng, P., Dome, J. S., Liu, Y., & Wang, Y. (2021) · Oncogene · doi:10.1038/s41388-021-01907-1 · Cited by 23 · see citing works
Satange, R., Chang, C.-C., Li, L., Lin, S., Neidle, S., & Hou, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad156 · Cited by 17 · see citing works
Thomas, A., Samykutty, A. K., Gómez-Gutiérrez, J. G., Yin, W., Egger, M. E., McNally, M. W., Chuong, P., MacCuaig, W. M., Albeituni, S., Zeiderman, M. R., et al. (2020) · Cancers · doi:10.3390/cancers12082279 · Cited by 17 · see citing works
RetractedChen, C., Chen, X., Ren, B., Guo, H., Abdel-Mageed, W. M., Liu, X., Song, F., & Zhang, L. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab079 · Cited by 14 · see citing works
Park, Y. S., Shin, W., Kim, C.-S., Ahn, C. M., Qi, X.-F., & Kim, S. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0002-8 · Cited by 14 · see citing works
Satange, R., Kao, S.-H., Chien, C., Chou, S., Lin, C., Neidle, S., & Hou, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac629 · Cited by 11 · see citing works
Echinomycin: A Journey of Challenges
Lafi, Z., Alshaer, W., Hatmal, M. M., Zihlif, M., Asha, N., Abdelnabi, H., & Awidi, A. (2023) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v16i3.918 · Cited by 11 · see citing works
Garcia, M. R., Andrade, P. B., Lefranc, F., & Gomes, N. G. M. (2024) · Marine Drugs · doi:10.3390/md22040143 · Cited by 11 · see citing works
Endophytic Microbes from Medicinal Plants in Fenghuang Mountain as a Source of Antibiotics
Yang, A., Hong, Y., Zhou, F., Zhang, L., Zhu, Y., Wang, C., Hu, Y., Yu, L., Chen, L., & Wang, X. (2023) · Molecules · doi:10.3390/molecules28176301 · Cited by 9 · see citing works
Xu, L., Ishikawa, H., Zhou, Y., Kobayashi, T., & Shozu, M. (2022) · F&S Science · doi:10.1016/j.xfss.2022.01.005 · Cited by 6 · see citing works
Zamudio-Vázquez, R., Alberício, F., Tulla‐Puche, J., & Fox, K. R. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400323x · Cited by 5 · see citing works
The bisintercalator family of nonribosomal peptides: structural diversity and biosynthetic mechanism
Shi, X. (2025) · Natural Product Reports · doi:10.1039/d5np00003c · Cited by 2 · see citing works
- Authors
- Schilsky, R. L., Faraggi, D., Korzun, A., Vogelzang, N., Ellerton, J., Wood, W., & Henderson, I. C.
- Venue
- Investigational New Drugs
- Published
- 1991-08
- Volume
- 9
- Issue
- 3
- Pages
- 269-272
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2077557214
- Cited by
- 21
- References
- 12
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2015: 1 · 2013: 1
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- T.J. Martell Foundation
- University of Chicago
- National Institutes of Health
- National Cancer Institute (CA-41287, U10CA011789, CA11789, U10CA033601, CA07968, U10CA031946, U10CA041287, U10CA035421)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- echinomycin, advanced breast cancer, metastatic breast cancer, breast cancer recurrence, intravenous chemotherapy, nausea and vomiting, elevated liver enzymes, anticancer activity, previously treated patients, survival
- MeSH terms
- Adenocarcinoma, Adult, Aged, Breast Neoplasms, Drug Evaluation, Echinomycin, Female, Humans, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
